Shares of Pfizer ended lower on reports that the company is starting 20 clinical trials this year and more soon after on treatments to conquer cancer as it also seeks to gain leadership in one of the hottest, and most lucrative, areas of medicine.
| Subscribe To Our Free Newsletter |
